RxSight's Stellar 2024 Performance and 2025 Growth Prospects
Generado por agente de IAWesley Park
domingo, 12 de enero de 2025, 9:41 am ET1 min de lectura
RXST--
RxSight, Inc. (NASDAQ: RXST), a leading ophthalmic medical device company, has announced its preliminary unaudited fourth quarter and full-year 2024 financial and operational results, as well as its 2025 guidance. The company's strong performance and growth prospects have been driven by its innovative Light Adjustable Lens (LAL) technology and expanding installed base of Light Delivery Devices (LDDs).
In the fourth quarter of 2024, RxSight achieved record highs for LDD sales and LAL procedures, meaningfully exceeding its initial full-year 2024 revenue guidance. The company sold 29,069 LALs, representing a 61% increase in procedure volume compared to the fourth quarter of 2023, and 83 LDDs, expanding its installed base to 971 LDDs as of December 31, 2024. This growth reflects the growing recognition of the superior visual outcomes enabled by adjustability, as well as the expanding infrastructure for post-operative light treatments.
For the full year 2024, RxSight's fiscal year revenue is expected to be approximately $139.9 million, representing growth of approximately 57% compared to the prior year. This growth is driven by the sale of 98,055 LALs and 305 LDDs. The company's preliminary unaudited cash, cash equivalents, and short-term investments as of December 31, 2024, is expected to be $237.2 million.
Looking ahead to 2025, RxSight anticipates full-year revenue in the range of $185.0 million to $197.0 million, reflecting growth of approximately 32% to 41% over 2024. The company currently estimates the full-year 2025 gross profit margin to be in the 71% to 73% range. In addition, the company expects full-year 2025 operating expenses in the range of $165.0 million to $170.0 million, including non-cash stock-based compensation expense guidance in the range of $22.0 million to $25.0 million.
RxSight's strong performance and growth prospects are driven by its innovative LAL technology, expanding installed base of LDDs, and international expansion strategy. The company's ability to deliver superior visual outcomes and expand its market share in the premium IOL market positions it well for continued success in the years to come. As Dr. Ron Kurtz, Chief Executive Officer and President of RxSight, stated, "We believe this sustained growth in one of ophthalmology’s most competitive segments reflects the growing recognition of the superior visual outcomes enabled by adjustability."
RxSight, Inc. (NASDAQ: RXST), a leading ophthalmic medical device company, has announced its preliminary unaudited fourth quarter and full-year 2024 financial and operational results, as well as its 2025 guidance. The company's strong performance and growth prospects have been driven by its innovative Light Adjustable Lens (LAL) technology and expanding installed base of Light Delivery Devices (LDDs).
In the fourth quarter of 2024, RxSight achieved record highs for LDD sales and LAL procedures, meaningfully exceeding its initial full-year 2024 revenue guidance. The company sold 29,069 LALs, representing a 61% increase in procedure volume compared to the fourth quarter of 2023, and 83 LDDs, expanding its installed base to 971 LDDs as of December 31, 2024. This growth reflects the growing recognition of the superior visual outcomes enabled by adjustability, as well as the expanding infrastructure for post-operative light treatments.
For the full year 2024, RxSight's fiscal year revenue is expected to be approximately $139.9 million, representing growth of approximately 57% compared to the prior year. This growth is driven by the sale of 98,055 LALs and 305 LDDs. The company's preliminary unaudited cash, cash equivalents, and short-term investments as of December 31, 2024, is expected to be $237.2 million.
Looking ahead to 2025, RxSight anticipates full-year revenue in the range of $185.0 million to $197.0 million, reflecting growth of approximately 32% to 41% over 2024. The company currently estimates the full-year 2025 gross profit margin to be in the 71% to 73% range. In addition, the company expects full-year 2025 operating expenses in the range of $165.0 million to $170.0 million, including non-cash stock-based compensation expense guidance in the range of $22.0 million to $25.0 million.
RxSight's strong performance and growth prospects are driven by its innovative LAL technology, expanding installed base of LDDs, and international expansion strategy. The company's ability to deliver superior visual outcomes and expand its market share in the premium IOL market positions it well for continued success in the years to come. As Dr. Ron Kurtz, Chief Executive Officer and President of RxSight, stated, "We believe this sustained growth in one of ophthalmology’s most competitive segments reflects the growing recognition of the superior visual outcomes enabled by adjustability."
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios